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ABSTRACT OBJECTIVES The aims of this study were to explore the relationship of baseline levels of natriuretic peptides (NPs) with outcomes and to test for an interaction between baseline levels of NPs and the effects spironolactone.
BACKGROUND Plasma NPs are considered to be helpful in the diagnosis of heart failure (HF) with preserved ejection fraction (HFpEF), and elevated levels are associated with adverse outcomes. Levels of NPs higher than certain cutoffs are often used as inclusion criteria in clinical trials of HFpEF to increase the likelihood that patients have HF and to select patients at higher risk for events. Whether treatments have a differential effect on outcomes across the spectrum of NP levels is unclear.
METHODS The TOPCAT (Treatment of Preserved Cardiac Function Heart
Failure With an Aldosterone Antagonist Trial) trial randomized patients with HFpEF and either prior hospitalization for HF or elevated natriuretic peptide levels (B-type NP [BNP] $100 pg/ml or N-terminal proBNP $360 pg/ml) to spironolactone or placebo. Baseline BNP (n ¼ 430) or N-terminal proBNP (n ¼ 257) levels were available in 687 patients enrolled from the Americas in the elevated-NP stratum of TOPCAT.
RESULTS Higher levels of NPs were independently associated with an increased risk for TOPCAT's primary endpoint of cardiovascular mortality, aborted cardiac arrest, or hospitalization for HF when analyzed either continuously or grouped by terciles, adjusting for region of enrollment, age, sex, atrial fibrillation, diabetes, renal function, body mass index, and heart rate. There was a significant interaction between the effect of spironolactone and baseline NP terciles for the primary outcome (p ¼ 0.017), with greater benefit of the drug in the lower compared with higher NP terciles.
CONCLUSIONS Similar to the effects of irbesartan in the I-PRESERVE (Irbesartan in Heart Failure With Preserved Ejection Fraction) trial, a greater benefit of spironolactone was observed in the group with lower levels of NPs and overall risk in TOPCAT. Elevated NPs in HFpEF identify patients at higher risk for events but who may be less responsive to treatment. The mechanism of this apparent interaction between disease severity and response to therapy requires P lasma natriuretic peptides (NPs) are elevated in patients with heart failure (HF) and preserved ejection fraction (HFpEF) and are associated with adverse outcomes (1, 2) . Clinical trials for the treatment of HF are often designed to include patients with plasma concentrations of NPs higher than certain cutoff levels to increase the likelihood that patients have HF and to select patients at higher risk for clinical events (3, 4) . Such an inclusion criterion is particularly relevant to patients with HFpEF, in whom the diagnosis of HF is often uncertain (5-7). However, the requirement for elevated NP levels comes at the expense of excluding approximately one-third of patients with HFpEF who have
Anand et al. Observing similar linear risk relationships for BNP and NT-proBNP levels, the groups were combined for further analyses. The combined NP was related to each study endpoint using Cox proportional hazards and
Poisson regression models adjusting for region, age, sex, atrial fibrillation, diabetes, eGFR, body mass index, and heart rate. The continuous relationship between the effect of spironolactone and NP was 
Anand et al. 145 to 391 pg/ml). NT-proBNP (n ¼ 257) ranged from 360 to 17,410 pg/ml (median 900 pg/ml; interquartile range: 557 to 1,920 pg/ml). The median and range of the NP values by tercile distribution are shown in Table 1 , which also shows the baseline characteristics of the 687 patients from the Americas by NP tercile. Patients with higher NP levels were older and more likely to have atrial fibrillation, chronic kidney disease, microalbuminuria, and lower albumin and less likely to be obese. They were also less likely to be taking aspirin but more likely to be taking long-acting nitrates.
A SINGLE, COMBINED NP SCORE. Baseline levels of both BNP and NT-proBNP in the 868 patients from the NP stratum had a similar linear relationship with the incidence of the primary outcome (p ¼ 0.54 for difference in overall risk relationship by NP type, p ¼ 0.33 for difference and NT-proBNP (n ¼ 257) subgroups of patients ( Figure 3) . When the analysis was repeated in the 868 
BASELINE ECHOCARDIOGRAPHIC VARIABLES BY TERCILE OF BASELINE BNP AND NT-proBNP LEVELS.
The TOPCAT echocardiographic substudy was carried out in 935 patients (10) . Of these, 473 patients also had baseline measurements of NPs (321 BNP and 152 NT-proBNP). Selected baseline echocardiographic variables in these 473 patients are shown in Online Table 1 . LV volumes and LV systolic function were not related to tercile of NP. However, higher NP tercile was associated with higher LV mass index and prevalence of LV hypertrophy, worse diastolic function (lower e 0 , higher E/e 0 ratio, larger left atrial volume index), and higher pulmonary pressure. In the 868 patients with NP levels available in the pre-specified NP stratum, only 268 had echocardiographic measurements at baseline, and only a few of them had full measurements of diastolic function. Nevertheless, even in this small group, higher NP tercile was associated with worse LV diastolic dysfunction (Online Table 2 ). Although post hoc subgroup analyses are generally considered to be hypothesis generating, it should be pointed out that our analyses of 868 TOPCAT subjects were based on the 981 patients in the NP stratum, 113 of whom did not have NP values. However, despite that, because they came from the NP stratum, the patients in the placebo and spironolactone groups were similar in all regards except treatment, because of randomization. As a consequence, the results derived within the NP stratum could be considered as "true" randomized evidence, and as expected, these patients were similar in all regards except treatment (Online Table 3 ). Therefore, it is possible to draw stronger conclusions and with greater reassurance than from other subgroup analyses that are not from a pre-specified randomized stratum (11) (12) (13) .
Several complementary analyses of these data confirm that the beneficial effects of the mineralocorticoid receptor antagonist spironolactone are more likely to be seen in patients with lower rather than higher levels of NPs. These data support the previous findings from the I-PRESERVE trial, in which the angiotensin receptor blocker irbesartan was shown to have no benefit in the overall population of patients with HFpEF but significantly reduced all outcomes in patients with low but not high NP levels (2) . How can we explain these intriguing findings? In both I-PRESERVE and TOPCAT, patients with higher NP Although the benefit of spironolactone in reducing cardiovascular events appears to be greatest in those patients in whom BNP or NT-proBNP was in the lower tercile, independent of LVEF, it should be pointed out that in a previous analysis of the TOPCAT data (19) , the benefits of spironolactone appeared to be greater in patients with LVEFs >45% to #60%, suggests that drug intervention may be successful early but not later in the natural history of the HFpEF syndrome, when structural changes in the heart might not be responsive to a therapeutic intervention. These data also suggest that we should not assume that patients at higher risk are always more likely to benefit from a treatment but do not provide the best NP cutoff for selecting more responsive patients. Nevertheless, the findings of this study need to be confirmed, and the strategy of using However, the notion that high-risk patients with HFpEF are more likely to benefit from treatments is not well established. We tested this hypothesis in patients from TOPCAT who had baseline measurements of BNP or NT-proBNP. Overall, spironolactone had no significant effect on the primary endpoint of cardiovascular mortality, aborted cardiac arrest, or hospitalization for HF in the entire population. However, a significant interaction was observed between the effect of spironolactone and NP levels (interaction p < 0.02), with most of the benefit of spironolactone seen in patients with low levels of NPs and no effect in patients with high NP levels. This apparent beneficial effect of the spironolactone in lower risk patients with HFpEF suggests that drug intervention may be successful early but not later in the natural history of HFpEF, when structural changes in the heart may not be responsive to a therapeutic intervention.
These data also suggest that the concept that patients at higher risk are more likely to benefit from treatment may not be correct. Thus, the strategy of using elevated plasma concentrations of NPs as a patient selection criterion in trials of HFpEF needs to be re-examined in prospectively designed clinical trials.
TRANSLATIONAL OUTLOOK: One of the important objectives in HF research is to identify patients to more precisely tailor specific therapies for those who are most likely to benefit from certain pharmaceutical agents or strategies of care. Several strategies are being considered, including the use of single or multiple biomarkers to guide approaches to categorizing patients. In this study, we show that the strategy of excluding patients with HFpEF with plasma NP concentrations less than certain thresholds from clinical trials to ensure enrollment of high-risk patients, who may not only have more outcomes but also be more likely to show a greater response to therapy, may need to be re-examined. We found that the beneficial effect of spironolactone was seen only in patients with low, not high, NP levels.
Further studies are required to test the interaction between biomarker levels and treatment effect. Anand et al.
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